Ohio State University Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.osu.edu

Clinical Trials

Fast Food, Fatigue, and Inflammation

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Saturated Fat Meal
Other: Oleic Sunflower Oil Meal

First Posted Date: 2020-01-30

Last Posted Date: 2023-09-06

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 58

Registration Number: NCT04247763

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Resiliency Among Older Adults Receiving Lung Cancer Treatment

Not Applicable

Completed

Conditions: Unresectable Lung Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma
Advanced Lung Carcinoma
Extensive Stage Lung Small Cell Carcinoma
Stage IIIA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8

Interventions: Procedure: Physical Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Relaxation Therapy

First Posted Date: 2020-01-18

Last Posted Date: 2023-11-15

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT04229381

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Phase 1

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8

Interventions: Drug: Nilotinib
Drug: Nilotinib Hydrochloride Monohydrate
Other: Placebo
Other: Questionnaire Administration
Drug: Paclitaxel

First Posted Date: 2019-12-20

Last Posted Date: 2023-02-27

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04205903

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Phase 1

Withdrawn

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Chemotherapy-Induced Peripheral Neuropathy
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8

Interventions: Drug: Lorcaserin
Drug: Lorcaserin Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2019-12-19

Last Posted Date: 2021-01-19

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT04205071

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Not Applicable

Withdrawn

Conditions: Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Radiation: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography

First Posted Date: 2019-10-28

Last Posted Date: 2024-03-08

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT04140513

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IVB Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8

Interventions: Biological: Pembrolizumab
Biological: Ramucirumab

First Posted Date: 2019-10-09

Last Posted Date: 2023-10-11

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT04120454

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Endobronchial Ultrasound-Guided Transbronchial Needle-Aspiration with Suction in Obtaining Samples from Patients with Suspected Nodal Metastatic Lung Cancer

Not Applicable

Recruiting

Conditions: Lung Carcinoma

Interventions: Procedure: Bronchoscopy
Procedure: Ultrasound-Guided Transbronchial Needle Aspiration

First Posted Date: 2019-10-07

Last Posted Date: 2024-10-31

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 263

Registration Number: NCT04116970

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Phase 1

Recruiting

Conditions: Persistent Disease
Refractory Acute Myeloid Leukemia
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2019-08-08

Last Posted Date: 2023-09-08

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT04049539

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

HPV Vaccine Intervention for Young Sexual Minority Men

Not Applicable

Active, not recruiting

Conditions: Healthy Subject

Interventions: Other: Best Practice
Other: Informational Intervention
Other: Questionnaire Administration
Behavioral: Text Message-Based Intervention

First Posted Date: 2019-07-25

Last Posted Date: 2024-05-21

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 1227

Registration Number: NCT04032106

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Recruiting

Conditions: Breast Cancer

Interventions: Other: Specimen collection

First Posted Date: 2019-07-17

Last Posted Date: 2024-03-08

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 99

Registration Number: NCT04022616

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy